ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Basaglar (insulin glargine) by Year
Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Basaglar (insulin glargine): $677M in FY2024, down 7.1% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 677 | -7.1% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 728 | -4.2% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 760 | -14.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 893 | -20.6% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 1,124 | +1.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 1,113 | +38.9% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 801 | +85.4% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 432 | +401.9% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 86.1 | +675.7% | Form 10-K (filed 2019-02-19) ↗ |
| FY2015 | Dec 31, 2015 | 11.1 | – | Form 10-K (filed 2017-02-21) ↗ |
| FY2014 | Dec 31, 2014 | 0 | – | Form 10-K (filed 2017-02-21) ↗ |
Breakdown
What makes up basaglar (insulin glargine)
Cite this data
StockData. (2026). Eli Lilly Basaglar (insulin glargine) ($M), annual FY2014–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-basaglar-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.